Skip to main content
TipRanks
Go Ultimate75% OFF

Harrow Health (HROW) Q3 2026 Earnings Report

638 Followers

HROW Q3 2026 EPS Results

Actual EPS
$0.25
Consensus EPS
$0.19
Beat/Miss
Beat by +$0.06
One Year Ago EPS
$0.03

HROW Q3 2026 Revenue Results

Actual Revenue
$99.30M
Expected Revenue
$98.59M
Beat/Miss
Beat by +$702.00K
YoY Revenue Growth
+38.61%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/09/2026
Time
After Close
Conference Call
Monday, November 9, 2026
HROW Upcoming Earnings

Harrow Health's next earnings date is estimated for March 8, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

HROW Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 09, 2026|% Change Since:10.70%|
Earnings Call Sentiment|Positive

The call was broadly positive, supported by record revenue, strong VEVYE and TRIESENCE growth, expanding payer coverage, commercial-force productivity, progress with TYRVAYA and G-MELT, and reaffirmed full-year revenue guidance. However, the reduced adjusted EBITDA outlook, lower-than-expected gross margins, the first-half revenue shortfall, BYOOVIZ's initially shallow launch, the IHEEZO Q3 sequential decline, the QUELL primary-endpoint miss, and the disclosed VEVYE licensing matter were meaningful challenges. Highlights significantly outweighed the lowlights.

Company Guidance

Harrow reaffirmed full year revenue guidance of $350 million to $365 million, implying Q4 revenue of roughly $136 million to $151 million or approximately 37% to 52% sequential growth, and expects the fourth quarter to be the strongest quarter in Harrow's history; it updated full year adjusted EBITDA outlook to more than $40 million, including more than $33 million in the fourth quarter, providing a floor rather than a range with room to outperform that level. Management expects growth quarter-over-quarter from VEVYE, continued contribution from TRIESENCE, sequential growth for IHEEZO, continued growth for BYOOVIZ, and TYRVAYA's best quarter in Q4, with TYRVAYA expected to do over $30 million of revenue next year; 2027 is expected to be a stronger year for volumes and revenue for IHEEZO than 2026, G-MELT is expected to be submitted later this month or the beginning of next month with a PDUFA goal date next year, the TRIESENCE Phase 3 readout is anticipated next year, specifically towards the end of first quarter, beginning of second quarter, and R&D as a percent of revenue should be roughly the same as where it is now.

  • Record Third-Quarter RevenueThird-quarter revenue reached a record $99.3 million, up 41% sequentially and 39% year-over-year. Branded revenue was $83.5 million, up about 62% year-over-year and representing roughly 84% of total revenue.
  • Positive Net Income and Adjusted EBITDA InflectionGAAP net income was $9.8 million, while adjusted EBITDA was $21.2 million compared with an adjusted EBITDA loss of $1.2 million in Q2. The company ended September with $75.3 million in cash and cash equivalents.
  • VEVYE Revenue and Prescription GrowthVEVYE generated $39.7 million of revenue, with revenue up 35% sequentially. Total prescriptions grew 17% sequentially and 83% year-over-year as the expanded field team became more productive and prescription economics improved.
  • VEVYE Coverage ExpansionHarrow expanded VEVYE coverage through a major national plan covering approximately 10 million lives effective January. Management described this as the company's third coverage win of the year and said covered prescriptions, including Medicare prescriptions, were rising.
  • Expanded Commercial OrganizationFollowing the addition of TYRVAYA, Harrow realigned its commercial organization into four focused teams: Ocular Surface Disease, Retina, Surgical and Access+. Management said the VEVYE key account manager footprint has more than tripled since the beginning of the year, while the TYRVAYA sales representative base has essentially doubled.
  • HarrowRx Platform LaunchHarrow launched HarrowRx as a single destination integrated primarily into existing electronic medical record workflows, allowing providers to access the company's portfolio of more than 20 branded products and related prior-authorization and specialty-pharmacy services.
  • TRIESENCE MomentumTRIESENCE generated $10.7 million of revenue, and unit demand reached 20,022, up 37% sequentially and 110% year-over-year. Management said this was the product's strongest quarter since relaunch and that ocular-inflammation use cases and treatment-protocol adoption were driving demand.
  • Significant TRIESENCE Market OpportunityManagement stated that TRIESENCE penetration remains in the low single digits, describing the product's current volume as a very small percentage of the overall market opportunity.
  • IHEEZO Underlying Demand and Seasonal OpportunityIHEEZO generated $25.3 million of revenue. Unit demand was 62,210, up 21% year-over-year, and management expects sequential demand growth with the potential for a new quarterly record in Q4. New retina account wins and deeper penetration of existing accounts have more than offset units lost after pass-through status expired in the ASC setting.
  • Encouraging QUELL Secondary FindingsAlthough QUELL did not meet its primary endpoint, exploratory findings showed identical cumulative pain scores of 2.0 immediately before and after injection for IHEEZO and routine anesthesia. Through 24 hours, cumulative pain scores were 2.9 for IHEEZO versus 3.7 for routine anesthesia; mean ocular-surface staining increased 1.7 versus 3.2; and adverse events occurred in 27% of IHEEZO patients versus 47% with routine anesthesia. No serious adverse events occurred in either group.
  • BYOOVIZ Reimbursement and Reorder ProgressBYOOVIZ received more initial account orders than expected, and early reimbursement experience was favorable. Several accounts reordered, payer coverage was described as receptive, and demand strengthened through September and into Q4.
  • TYRVAYA IntegrationApproximately 40 experienced TYRVAYA sales representatives and their managers joined Harrow from Viatris and were already calling on familiar practices. Management said prescription demand was beginning to grow under Harrow, with TYRVAYA contributing revenue in Q4.
  • Full-Year Revenue Guidance ReaffirmedHarrow reaffirmed full-year revenue guidance of $350 million to $365 million. This implies Q4 revenue of roughly $136 million to $151 million, or approximately 37% to 52% sequential growth, supported by VEVYE, IHEEZO, TRIESENCE, BYOOVIZ and TYRVAYA.
  • G-MELT NDA ProgressHarrow completed its pre-NDA meeting with the FDA and remains on track to submit the G-MELT NDA later this month or at the beginning of next month, meaningfully earlier than originally expected. Management anticipates a PDUFA goal date in 2027.
  • Development Programs AdvancingR&D programs accelerated ahead of schedule, primarily reflecting G-MELT NDA-enabling work and clinical studies for IHEEZO and TRIESENCE. The Phase 3 TRIESENCE study is enrolling on track, with a readout anticipated toward the end of the first quarter or beginning of the second quarter of next year.
  • Growth in Additional Ocular Surface ProductsManagement cited momentum in VERKAZIA and NATACYN as the expanded Ocular Surface Disease team provides physicians with access information for these products, including NATACYN for fungal infections and VERKAZIA as a steroid-sparing product for severe allergies.

HROW Earnings History

HROW earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 08, 20272026 (Q4)0.57-0.17――
Nov 09, 20262026 (Q3)0.190.250.03733.33% (+0.22)
Aug 10, 20262026 (Q2)-0.18-0.460.13-453.85% (-0.59)
May 11, 20262026 (Q1)-0.40-0.74-0.5-48.00% (-0.24)
Mar 02, 20262025 (Q4)0.370.170.24-29.17% (-0.07)
Nov 10, 20252025 (Q3)0.210.03-0.12125.00% (+0.15)
Aug 11, 20252025 (Q2)0.010.13-0.18172.22% (+0.31)
May 08, 20252025 (Q1)-0.05-0.50-0.38-31.58% (-0.12)
Mar 27, 20252024 (Q4)0.080.24-0.26192.31% (+0.50)
Nov 13, 20242024 (Q3)-0.05-0.12-0.137.69% (+0.01)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed